Archived: Bonding for Life: Covalent Inhibition in Drug Discovery
Date: 13 May 2021
Time: 15:00 (BST), 16.00 (CEST), 10.00 (EDT), 7.00 (PDT)
Irreversibly binding a small molecule drug to an enzyme and permanently disabling its function is not a new concept in the treatment of human disease. Over 40 covalent modifier drugs have been approved for clinical use by the FDA. Despite this fact, resistance in the pharmaceutical industry due to concerns about safety and off-target binding has propagated the view that development of a covalent inhibitor is a high risk strategy.
In this webinar, we traced the history of covalent inhibition in the pharmaceutical industry, highlighting the successes (and the horror stories), the strategies employed and where this is leading us.
This webinar was presented by Dr John Studley, Scientific Update.